Acea Biosciences

ACEA's xCELLigence impedance-based, label-free, real-time cell analysis instruments are used in immuno-oncology pre-clinical drug discovery and development.

IP Roundup

Premium

Yale University, University of South Florida, Alabama State University, Stanford University, SRU Biosystems, Eppendorf Array Technology, Agilent Technologies, Acea Biosciences

The new label-free and real-time cell-based assays will incorporate Vivo's HuBiogel platform.

The firms are developing a system for the early and accurate prediction of cardiotoxic side effects in the drug discovery process.

The US Environmental Protection Agency this week presented for the first time initial data from the first phase of its ToxCast program during the Society of Toxicology's annual meeting, held this year in Baltimore, according to an official from a company who participated in the p

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.